Literature DB >> 18442986

Vascular tolerance to nitroglycerin in ascorbate deficiency.

Gerald Wölkart1, M Verena Wenzl, Matteo Beretta, Heike Stessel, Kurt Schmidt, Bernd Mayer.   

Abstract

AIMS: Nitroglycerin (GTN) acts through release of a nitric oxide (NO)-related activator of soluble guanylate cyclase in vascular smooth muscle. Besides enzymatic GTN bioactivation catalysed by aldehyde dehydrogenase, non-enzymatic reaction of GTN with ascorbate also results in the formation of a bioactive product. Using an established guinea pig model of ascorbate deficiency, we investigated whether endogenous ascorbate contributes to GTN-induced vasodilation. METHODS AND
RESULTS: Guinea pigs were fed either standard or ascorbate-free diet for 2 or 4 weeks prior to measuring the GTN response of aortic rings and isolated hearts. The effects of ascorbate on GTN metabolism were studied with purified mitochondrial aldehyde dehydrogenase (ALDH2) and isolated mitochondria. Ascorbate deprivation led to severe scorbutic symptoms and loss of body weight, but had no (2 weeks) or only slight (4 weeks) effects on aortic relaxations to a direct NO donor. The EC(50) of GTN was increased from 0.058 +/- 0.018 to 0.46 +/- 0.066 and 5.5 +/- 0.9 microM after 2 and 4 weeks of ascorbate-free diet, respectively. Similarly, coronary vasodilation to GTN was severely impaired in ascorbate deficiency. The potency of GTN was reduced to a similar extent by ALDH inhibitors in control and ascorbate-deficient blood vessels. Up to 10 mM ascorbate had no effect on GTN metabolism catalysed by purified ALDH2 or liver mitochondria isolated from ascorbate-deficient guinea pigs.
CONCLUSION: Our results indicate that prolonged ascorbate deficiency causes tolerance to GTN without affecting NO/cyclic GMP-mediated vasorelaxation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18442986     DOI: 10.1093/cvr/cvn107

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  8 in total

Review 1.  A physiologically relevant role for NO stored in vascular smooth muscle cells: A novel theory of vascular NO signaling.

Authors:  Taiming Liu; Hobe Schroeder; Gordon G Power; Arlin B Blood
Journal:  Redox Biol       Date:  2022-05-09       Impact factor: 10.787

Review 2.  The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles.

Authors:  B Mayer; M Beretta
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

3.  Understanding organic nitrates--a vein hope?

Authors:  Mark R Miller; Roger M Wadsworth
Journal:  Br J Pharmacol       Date:  2009-06       Impact factor: 8.739

Review 4.  Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress.

Authors:  Andreas Daiber; Thomas Münzel
Journal:  Antioxid Redox Signal       Date:  2015-09-24       Impact factor: 8.401

5.  Different effects of ascorbate deprivation and classical vascular nitrate tolerance on aldehyde dehydrogenase-catalysed bioactivation of nitroglycerin.

Authors:  M V Wenzl; G Wölkart; H Stessel; M Beretta; K Schmidt; B Mayer
Journal:  Br J Pharmacol       Date:  2009-02-27       Impact factor: 8.739

Review 6.  Myths, artifacts, and fatal flaws: identifying limitations and opportunities in vitamin C research.

Authors:  Alexander J Michels; Balz Frei
Journal:  Nutrients       Date:  2013-12-16       Impact factor: 5.717

7.  Aldehyde dehydrogenase-independent bioactivation of nitroglycerin in porcine and bovine blood vessels.

Authors:  Regina Neubauer; Gerald Wölkart; Marissa Opelt; Christine Schwarzenegger; Marielies Hofinger; Andrea Neubauer; Alexander Kollau; Kurt Schmidt; Astrid Schrammel; Bernd Mayer
Journal:  Biochem Pharmacol       Date:  2015-01-08       Impact factor: 5.858

8.  Tolerance to nitroglycerin through proteasomal down-regulation of aldehyde dehydrogenase-2 in a genetic mouse model of ascorbate deficiency.

Authors:  G Wölkart; M Beretta; M V Wenzl; H Stessel; K Schmidt; N Maeda; B Mayer; A Schrammel
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.